Dihexa: Extreme Preclinical Potency, No Human Data

Dihexa, also written PNB-0408 or N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, is a small peptide derived from angiotensin IV. It generated attention because of exceptionally potent preclinical results, and it warrants careful handling because the mechanism producing those results is one with recognized oncologic significance.

This guide situates Dihexa within the broader field of peptide therapy and is written for clinicians. It is clinical education, not medical advice, and nothing here should be read as a treatment recommendation or protocol.

What Dihexa is

Dihexa is a modified small peptide developed from angiotensin IV, a fragment of the angiotensin peptide family better known for blood pressure regulation. The brain has its own renin-angiotensin system, and angiotensin IV has been associated with effects on learning and memory distinct from the peripheral cardiovascular actions.

The molecule was modified specifically to improve metabolic stability and blood-brain barrier penetration, addressing the usual obstacles to peptide activity in the central nervous system.

It was developed in an academic research setting studying cognitive impairment and neurodegeneration.

The HGF/c-Met mechanism

Dihexa's proposed mechanism is potentiation of hepatocyte growth factor signalling at its receptor, c-Met. Rather than acting as a receptor agonist itself, it appears to enhance the activity of endogenous HGF at that receptor.

HGF/c-Met signalling drives cell survival, proliferation, migration and morphogenesis across many tissues. In the nervous system it supports neuronal survival and synapse formation.

Preclinical reports described synaptogenic potency described as orders of magnitude greater than BDNF in the systems tested, alongside improvements in animal models of cognitive impairment. Those are genuinely arresting findings, and they are the source of the compound's reputation.

Why the potency is a warning rather than a selling point

The HGF/c-Met axis is one of the more thoroughly characterized oncogenic signalling pathways in medicine. Aberrant c-Met activation is implicated in the development, invasion and metastasis of multiple cancers, and a substantial pharmaceutical effort has been directed at developing c-Met inhibitors as anticancer drugs.

This creates an unavoidable tension. Dihexa's mechanism is potentiation of a pathway that oncology invests heavily in blocking. A compound that powerfully amplifies pro-survival, pro-proliferative, pro-migratory signalling is not one whose potency should be reassuring in the absence of safety data.

There is no human clinical trial data on Dihexa. No study has characterized its safety, its dosing, its pharmacokinetics in people, or its effects over any duration — including on occult malignancy.

This is the clearest case in the formulary where impressive preclinical potency should increase caution rather than confidence. The same property producing the synaptic results is the property warranting concern.

Regulatory status — stated precisely

Dihexa was among the twelve peptides removed from FDA Category 2 on April 15, 2026. As set out in our PEG-MGF guide, removal from Category 2 is not approval. It lifts a significant-safety-risk designation and returns the substance to pending evaluation; it does not place it on the 503A bulks list or make it an approved drug.

That distinction is especially consequential here. A compound with no human data and a mechanism intersecting a major oncogenic pathway should not be presented as validated on the basis of a change in regulatory categorization.

Dihexa is sold online as a research chemical. For any patient using it, the oncologic considerations above should be discussed directly. Our peptide formulary carries current status for every agent.